Know now: New version of Trametinib instruction manual online

1. Drug name

Trametinib

2. Indications

1.Untreated BRAF V600E or V600K mutation-positive advanced or metastatic malignant melanoma;

2.Combined use with BRAF V600E or V600K mutation-positive metastatic non-small cell lung cancer (NSCLC) in patients with dabrafenib;

3.BRAF V600E or V600K combination application in patients with mutation-positive metastatic colorectal cancer (mCRC).

3. Usage and dosage

1.Trametinib tablets are administered orally.

2.Usual dosage: Adult patients are 2mg (mg) once daily. Dosage may be adjusted based on patient tolerance and efficacy. Dosage and usage in pediatric patients should be based on weight and age and should be directed by a physician.

3.Trametinib is recommended to be taken on an empty stomach at least one hour before or after a meal, and avoid taking it at the same time with foods containing calcium ions.

4.If the patient forgets to take the medication, he should continue taking the medication at the next normal medication time without supplementary doses.

4. Contraindications

1.Contraindicated in patients allergic to trametinib or any of its components.

2.It is contraindicated in patients with severe cardiovascular diseases, such as myocardial infarction, unstable angina, etc.

5. Things to note

1.During the period of treatment with trametinib, patients should regularly monitor blood, liver function and eye conditions, and conduct electrocardiogram monitoring to monitor the patient's treatment response and adverse reactions.

2.Trametinib may cause adverse reactions, including but not limited to rash, diarrhea, fatigue, hypertension, visual impairment, etc. Patients should pay close attention to these reactions and report them to their doctor promptly.

3.Trametinib may interact with other drugs, including but not limited toCYP3A4 inhibitors and inducers, therefore concomitant use with these drugs should be avoided during treatment with trametinib.

6. Adverse reactions

1.Common adverse reactions of trametinib include rash, diarrhea, fatigue, nausea, vomiting, hypertension, visual impairment, etc.

2.Some patients may experience serious adverse reactions, such as lung disease, abnormal liver function, cardiovascular events, etc., which require timely diagnosis and treatment.

7. Drug interactions

1.Trametinib may interact with other drugs, including but not limited toCYP3A4Inhibitors and inducers, patients should avoid concurrent use of these drugs while receiving trametinib.

2.Patients should consult a doctor or pharmacist before using other drugs to avoid drug interactions.

8. Storage

1.Trametinib tablets should be stored in a cool, dry place away from direct sunlight.

2.Please keep trametinib away from children to avoid accidental ingestion.

9. Production enterprises

Trametinib is produced by approved manufacturers to ensure product quality and safety.

10. Remarks

1.Patients should undergo regular reexamination and monitoring while using trametinib to ensure efficacy and safety.

2.If you have any discomfort or questions, please consult your doctor or pharmacist in time.

Trametinib has been launched in the domestic market and has been included in medical insurance. Patients can purchase it domestically at an approximate price of more than 10,000 yuan. The price is relatively high, but you need to consult the local hospital pharmacy for specific costs. In foreign countries, the price of trametinib is relatively low, mainly because there are many generic drugs to choose from, especially the generic drugs produced in Laos, which cost about one to two thousand yuan, which is much cheaper than in China. It should be noted that the ingredients of foreign generic drugs and domestic original drugs are basically the same.

xa0